BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares and Closing of the Concurrent Private Placement
01 Octobre 2024 - 10:30PM
BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage
biopharmaceutical company developing therapeutic product candidates
for metabolic diseases, such as obesity, by targeting the biology
of aging, today announced the closing of its upsized initial public
offering of 12,650,000 shares of its common stock, which includes
the exercise in full by the underwriters of their option to
purchase 1,650,000 additional shares, at the initial public
offering price of $18.00 per share. All of the shares were offered
by BioAge.
In addition to the shares sold in the initial
public offering, BioAge today announced the closing on September
27, 2024 of its sale of 588,888 shares of its common stock at the
initial public offering price per share in a concurrent private
placement to an existing stockholder. The sale of the shares of
common stock in the concurrent private placement was not registered
under the Securities Act of 1933, as amended.
Goldman Sachs & Co. LLC, Morgan Stanley,
Jefferies, and Citigroup acted as joint book-running managers for
the offering and as placement agents for the concurrent private
placement.
The gross proceeds to BioAge from the initial
public offering, including full exercise of the underwriters’
option to purchase additional shares, and the concurrent private
placement, before deducting underwriting discounts and commissions,
placement agent fees and offering and private placement expenses,
were approximately $238.3 million.
Registration statements relating to the
securities issued and sold in the initial public offering have been
filed with the U.S. Securities and Exchange Commission (SEC) and
became effective on September 25, 2024. A prospectus relating to
and describing the terms of the initial public offering has been
filed with the SEC and is available on the SEC's website at
www.sec.gov. The initial public offering was made only by means of
a prospectus. Copies of the final prospectus may be obtained from
Goldman Sachs & Co. LLC, Attention: Prospectus
Department, 200 West Street, New York, NY 10282, by
telephone at (866) 471-2526, or by email
at Prospectus-ny@ny.email.gs.com; Morgan Stanley & Co.
LLC, Attention: Prospectus Department, 180 Varick Street, 2nd
Floor, New York, NY 10014, or by email at
prospectus@morganstanley.com; Jefferies LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, New York, NY
10022, by telephone at (877) 821-7388, or by email at
Prospectus_Department@Jefferies.com; Citigroup, c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717,
by telephone at 800-831-9146.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy these securities,
nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About BioAge Labs
BioAge is a clinical-stage biopharmaceutical
company developing therapeutic product candidates for metabolic
diseases, such as obesity, by targeting the biology of human aging.
BioAge’s lead product candidate, azelaprag, is an orally available
small molecule agonist of APJ that has been well-tolerated in 265
individuals across eight Phase 1 clinical trials, including a Phase
1b clinical trial where decreased muscle atrophy, preservation of
muscle quality and improved metabolism were observed in subjects
treated with azelaprag over a 10-day period. In mid-2024, BioAge
initiated a Phase 2 trial of azelaprag in combination with
tirzepatide for the treatment of obesity in older adults. Azelaprag
has potential as an oral regimen to improve weight loss and restore
both body composition and muscle function in patients on obesity
therapy with incretin drugs. BioAge is also developing orally
available small molecule brain penetrant NLRP3 inhibitors for the
treatment of diseases driven by neuroinflammation. BioAge’s
preclinical programs, based on novel insights from the BioAge’s
discovery platform built on human longevity data, also have the
potential to address key pathways in metabolic aging.
ContactsPR: Chris Patil,
media@bioagelabs.com IR: Elena Liapounova, ir@bioagelabs.com
Partnering: partnering@bioagelabs.com
BioAge Labs (NASDAQ:BIOA)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
BioAge Labs (NASDAQ:BIOA)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024